P-272 Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab

Annals of Oncology ◽

10.1093/annonc/mdv233.269 ◽

2015 ◽

Vol 26 ◽

pp. iv80

Author(s):

P. García Alfonso ◽

M.J. Ortiz ◽

G. Durán ◽

E. Falcó ◽

A. Muñoz ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Braf Mutation ◽

Phase Ii Study ◽

Single Agent ◽

Previously Treated

Download Full-text

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

10.1186/s12885-019-5753-7 ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

A. Carrato ◽

M. Benavides ◽

B. Massutí ◽

R. Ferreiro-Monteagudo ◽

P. García Alfonso ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Cooperative Group ◽

Pilot Phase ◽

Download Full-text

Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3580 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3580-3580 ◽

Author(s):

J. A. Meyerhardt ◽

A. Xhu ◽

P. C. Enzinger ◽

D. P. Ryan ◽

J. W. Clark ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps3662 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3662-TPS3662

Author(s):

Kohei Shitara ◽

Kentaro Yamazaki ◽

Hiroyuki Uetake ◽

Takeshi Kato ◽

Eiji Oki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated

Download Full-text

Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e14524 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e14524-e14524

Author(s):

Alfredo Carrato ◽

Bartolomeu Massuti Sureda ◽

Manuel Benavides ◽

Carmen Guillén Ponce ◽

Esther Falco ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Tumor Therapy ◽

Single Agent ◽

Cooperative Group ◽

Line Treatment ◽

First Line Treatment

Download Full-text

A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer – DEREGULATE study - Trial in progress

Annals of Oncology ◽

10.1093/annonc/mdy151.291 ◽

2018 ◽

Vol 29 ◽

pp. v82

Author(s):

K. Kawaguchi ◽

R. Nishitai ◽

D. Manaka ◽

T. Ota ◽

Y. Nishikawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Dose Escalation ◽

Phase Ii Study ◽

Study Trial ◽

Previously Treated

Download Full-text

Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.3527 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 3527-3527 ◽

Author(s):

Alfredo Carrato ◽

Manuel Benavides ◽

Bartolomeu Massuti Sureda ◽

Federico Longo ◽

Pilar Garcia Alfonso ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Tumor Therapy ◽

Single Agent ◽

Cooperative Group ◽

Line Treatment ◽

First Line Treatment

Download Full-text

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.3510 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 3510-3510 ◽

Author(s):

Yasushi Tsuji ◽

Kohei Shitara ◽

Takeharu Yamanaka ◽

Tadamichi Denda ◽

Katsunori Shinozaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Biomarker Analysis ◽

Reverse Sequence ◽

Previously Treated ◽

Colorectal Cancer Patients

Download Full-text

Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3255-3 ◽

2017 ◽

Vol 79 (3) ◽

pp. 579-585 ◽

Author(s):

Hidekazu Kuramochi ◽

Masayuki Ando ◽

Michio Itabashi ◽

Go Nakajima ◽

Kazuyuki Kawakami ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Previously Treated

Download Full-text

Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])

Annals of Oncology ◽

10.1093/annonc/mdu333.3 ◽

2014 ◽

Vol 25 ◽

pp. iv168 ◽

Author(s):

P. García Alfonso ◽

M. Benavides ◽

A. Sánchez Ruiz ◽

C. Guillen-Ponce ◽

M.J. Safont ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Cooperative Group ◽

Download Full-text